Bausch Health Companies Inc. (BHC) 2018 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by, and welcome to Valeant First Quarter 2018 Earnings Call. (Operator Instructions)

    各位女士、先生,感謝您稍候,歡迎參加 Valeant 2018 年第一季財報電話會議。(接線員指示)

  • I will now turn the call over to Mr. Art Shannon, Senior Vice President, Investor Relations. Please go ahead.

    現在我將把電話交給投資人關係資深副總裁 Art Shannon 先生。請開始。

  • Arthur J. Shannon - Senior VP and Head of IR & Communications

    Arthur J. Shannon - Senior VP and Head of IR & Communications

  • Thank you, Crystal, and good morning, everyone. Welcome to our first quarter 2018 financial results conference call. Participating on today's call are our Chairman and Chief Executive Officer, Mr. Joe Papa; Chief Financial Officer, Mr. Paul Herendeen; Mr. Mark McKenna, Senior Vice President and General Manager of Salix Pharmaceuticals. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.

    謝謝你,Crystal,各位早安。歡迎參加我們 2018 年第一季財務結果電話會議。今天與會者包括:我們的董事長兼執行長 Joe Papa 先生;財務長 Paul Herendeen 先生;以及 Salix Pharmaceuticals 資深副總裁兼總經理 Mark McKenna 先生。除本次即時網路直播外,今日簡報投影片的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。

  • Before we begin, we'd like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information.

    在開始之前,我們提醒各位,今天的簡報包含前瞻性資訊。請您花一點時間閱讀簡報開頭的前瞻性聲明說明,因其中包含重要資訊。

  • This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.

    本簡報包含非 GAAP 財務衡量指標。如需更多關於這些衡量指標的資訊,請參閱簡報第 2 頁。非 GAAP 調節表可於我們網站所發布之簡報附錄中查閱。

  • Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.

    最後,本簡報中的財務指引僅以今日為準。我們的政策通常是在下一季之前不更新指引,且除透過廣泛發布的公開揭露外,不會更新或確認指引。

  • With that, it is my pleasure to turn the call over to Joe.

    接下來,我很榮幸把電話交給 Joe。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Thanks, Art, and thank you, everyone, for joining our call. For today's call, first, I will cover the first quarter highlights, I'll then turn the call over to our CFO, Paul Herendeen, to review the first quarter results and update our 2018 guidance. Finally, we'll wrap up with a review of the segment highlights and 2018 catalyst, including an update on XIFAXAN from Mark McKenna, before opening the line for questions.

    謝謝你,Art,也謝謝各位參加我們的電話會議。今天的會議流程如下:首先我將說明第一季重點,接著把電話交給我們的財務長 Paul Herendeen,回顧第一季結果並更新我們 2018 年的指引。最後,在開放提問之前,我們將總結各事業部門重點與 2018 年催化劑(重要推動因素),其中也包括 Mark McKenna 對 XIFAXAN 的最新進展。

  • Beginning on Slide 4. We are now well in the turnaround phase of our multiyear plan, and we continue to make tangible progress towards transformation. Over the past 2 years, we've taken a number of steps to strengthen our core business and to refocus on areas in need of improvement. Our goal is for 2018 to be a year of operational excellence as we focus on what we refer to as Project CORE, C-O-R-E or cost optimization and revenue enhancement.

    從第 4 頁投影片開始。我們目前已穩步進入多年計畫的扭轉階段,並持續朝轉型目標取得具體進展。過去兩年,我們採取多項措施以強化核心業務,並重新聚焦於需要改善的領域。我們的目標是讓 2018 年成為營運卓越的一年,聚焦於我們所稱的 Project CORE(C-O-R-E),亦即成本最佳化與營收提升。

  • I think our great first quarter results demonstrate that we are on track, a special thanks to the 20-plus thousand dedicated employees that did a great job in turning around and transforming our company. Notably, for the first time since the third quarter of 2015, the company delivered overall organic revenue growth that tracked above expectations.

    我認為我們第一季優異的業績證明我們正按計畫推進;特別感謝兩萬多名敬業的員工,在扭轉與轉型公司方面表現出色。值得注意的是,自 2015 年第三季以來,公司首次實現整體有機營收成長,且表現高於預期。

  • Moving on to Slide 5. Keeping with the theme of operational excellence, let me give you some examples of what we have achieved as a result of the investment we have made and the steps we have taken to strengthen our core businesses. Revenues from the Bausch + Lomb/International and Salix continue to grow nicely, up 10% organically from Q1 '17, driven by strong growth in Salix -- or promoted products; Global Vision Care; international prescription business; and our Global Surgical. We also saw our top 10 products, which is -- are listed on Slide 32 in the appendix, grow by more than 20% in the aggregate compared to the first quarter of 2017.

    接著看第 5 頁投影片。延續營運卓越的主題,我舉幾個例子說明我們因投入資源並採取措施強化核心業務而達成的成果。Bausch + Lomb/International 與 Salix 的營收持續穩健成長,較 2017 年第一季有機成長 10%,主要由 Salix(或推廣產品)、全球視力照護、國際處方藥業務以及我們的全球外科業務強勁成長所帶動。我們也看到前 10 大產品(名單列於附錄第 32 頁投影片)合計較 2017 年第一季成長超過 20%。

  • At the same time, we are driving growth by advancing our new product pipeline and promoted products. The launches of RELISTOR, SILIQ, Vyzulta and LUMIFY, 4 of the significant 7, are currently underway. The Retin-A Micro 0.06% launch is tracking ahead of the company's expectations. We are conducting clinical trials to evaluate new formulations and new indications for Rifaximin, and we are promoting current branded products in our portfolio, like Migranal and Wellbutrin XL, which are benefiting from this refocus.

    同時,我們也透過推進新產品研發管線與推廣產品來帶動成長。RELISTOR、SILIQ、Vyzulta 與 LUMIFY(重要 7 項中的 4 項)目前正陸續上市推進中。Retin-A Micro 0.06% 的上市進度優於公司預期。我們正在進行臨床試驗,以評估 Rifaximin 的新配方與新適應症;同時也在推廣我們產品組合中的現有品牌產品,例如 Migranal 與 Wellbutrin XL,並已因這項重新聚焦而受益。

  • We've also made tangible progress on the debt reduction front. As of May 8, 2018, we have reduced total debt by approximately $6.9 billion since the end of the first quarter of 2016, which includes $280 million in the first quarter of 2018.

    我們在降低負債方面也取得具體進展。截至 2018 年 5 月 8 日,自 2016 年第一季末以來,我們已將總負債降低約 69 億美元,其中 2018 年第一季降低 2.8 億美元。

  • Finally, we continue to make progress in resolving legal issues. Since January 1, 2018, we resolved approximately 20 additional litigations and investigations. Some of our recent successes, the UCERIS Cosmo arbitration, was decided in our favor, and the tribunal ordered Cosmo to pay the entirety of Valeant's legal costs equivalent to $3 million. The court in our ANDA RELISTOR injectable case created partial summary judgment on the validity of the U.S. patent in our favor, protecting the formulation of our product to at least April 2024.

    最後,我們在解決法律議題方面持續取得進展。自 2018 年 1 月 1 日起,我們又解決了約 20 件訴訟與調查。我們近期的一些勝利包括:UCERIS Cosmo 仲裁案判決對我們有利,仲裁庭並命令 Cosmo 支付 Valeant 全部法律費用,約 300 萬美元。在我們的 ANDA RELISTOR 注射劑案件中,法院就美國專利有效性作出部分簡易判決對我們有利,保護我們產品配方至少至 2024 年 4 月。

  • We agreed to resolve the SOLODYN antitrust litigations, and for $1.875 million, we resolved another matter relating to our terminated relationship with Philidor by reaching a settlement agreement with the California Department of Insurance, with no admission or findings of facts or liability. You'll also recall in May 2017, the New Jersey State Bureau of Securities closed its investigation on the Philidor matter also, with no admission of facts or liability by the company. Importantly, we resolved cases that represent, in the aggregate, over $1 billion of alleged exposure, and our team has been able to do this for substantially less than initially claimed amount of exposure.

    我們同意解決 SOLODYN 反托拉斯訴訟;並以 187.5 萬美元,就與 Philidor 終止合作關係相關的另一事項,與加州保險局達成和解協議,且不承認亦不認定任何事實或責任。各位也記得,2017 年 5 月,新澤西州證券局亦結束對 Philidor 事項的調查,同樣未要求公司承認任何事實或責任。重要的是,我們解決的案件合計所主張的曝險超過 10 億美元,而我們團隊得以用遠低於最初主張曝險金額的成本完成處理。

  • Another item of important is the recent 90-day extension of the XIFAXAN ANDA case with Actavis, now Teva, which was filed on April 30, 2018 (sic) [2017]. As you know, 1 year ago, we agreed to a stay on the matter to provide Teva an opportunity to meet the revised draft guidance on rifaximin issued by the FDA. Not much has changed over the year, and Teva is still considering how to proceed. We believe that at this time, Teva does not have an improvable ANDA, and we continue to feel confident about the strength of our intellectual patent portfolio protecting XIFAXAN.

    另一項重要事項是,近期 XIFAXAN 與 Actavis(現為 Teva)的 ANDA 案件再度延長 90 天;該案於 2018 年 4 月 30 日(原文誤植)[2017] 提起。如各位所知,一年前我們同意暫緩此案,以提供 Teva 機會符合 FDA 就 rifaximin 所發布之修訂草案指引。一年來情況變化不大,Teva 仍在考量如何推進。我們相信目前 Teva 並沒有可核准的 ANDA,我們也持續對保護 XIFAXAN 的智慧財產與專利組合之強度充滿信心。

  • All in all, we had a great quarter of progress both on the legal front and in the businesses.

    總而言之,本季我們在法律面與業務面都取得了很好的進展。

  • On Slide 7, we present a snapshot of the Q1 financial highlights. To me, this slide says it all in terms of how we are executing on our plan. Overall, revenue, adjusted EBITDA, cash flow and adjusted net income in the quarter were above expectations. 76% of the quarter 1 revenue was generated by the Bausch + Lomb/International segment and the Salix business, which grew organically by 10% during the quarter combined. Specifically, the Branded Rx business delivered 8% organic revenue growth compared to Q1 2017, and B + L International grew modestly at 2%.

    在第 7 頁投影片,我們呈現第一季財務重點摘要。對我而言,這張投影片充分說明我們如何落實並執行計畫。整體而言,本季營收、調整後 EBITDA、現金流與調整後淨利均高於預期。第一季營收的 76% 來自 Bausch + Lomb/International 事業部與 Salix 業務;兩者合計在本季有機成長 10%。具體而言,品牌處方藥(Branded Rx)業務較 2017 年第一季實現 8% 的有機營收成長,而 B + L International 則小幅成長 2%。

  • And with that, I'll turn it over to Paul to take you through the financial results in further detail.

    說到這裡,我把時間交給 Paul,請他帶各位更深入地說明財務結果。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Thank you, Joe, and good morning. Just a quick reminder, whenever I talk about organic changes compared with the prior year, that means on a constant-currency basis and adjusted for the impact of divested assets.

    謝謝你,Joe,大家早安。先快速提醒一下,當我談到相較於前一年的有機變動時,指的是以固定匯率基礎計算,並且已調整剝離資產的影響。

  • Here we go. Start on Slide 8, and that provides a look at total company performance. We posted a solid first quarter, with revenue just shy of $2 billion. On a reported basis, revenue declined 5%. Adjusting for currency, which was a tailwind relative to the prior year, we were down 9%. However, divestitures accounted for an 11% year-over-year decline, so on an organic basis, we're up 2% compared with Q1 2017, as Joe said, the first time we posted company-wide organic revenue growth since Q2 of 2015.

    我們開始。請看第 8 張投影片,這裡提供公司整體表現概覽。我們第一季表現穩健,營收接近 20 億美元。以報表口徑計算,營收下滑 5%。若調整匯率(相較前一年為正面助力),則下滑 9%。不過,資產剝離造成了年對年 11% 的下滑,因此以有機口徑來看,正如 Joe 所說,相較 2017 年第一季我們成長 2%,這也是自 2015 年第二季以來首次出現全公司範圍的有機營收成長。

  • Our gross margin declined roughly 50 basis points, mainly due to mix driven by the declines in the high-margin LOE products in the U.S. Diversified Products segment. Total adjusted operating expenses were favorable to the prior year on an organic basis by 4%, with a reduction in corporate G&A expenses being the main driver. Our adjusted EBITDA was $832 million, down 3% on a reported basis, down 5% on a constant-currency basis and up 4% on an organic basis, again, adjusted by divestitures. The roughly $2.7 billion GAAP net loss in the quarter was driven in part by goodwill impairment charges of roughly $2.2 billion related to our early adoption of new rules to simplify the accounting for goodwill.

    我們的毛利率下滑約 50 個基點,主要是因為美國多元化產品(Diversified Products)事業部中高毛利的 LOE 產品下滑所帶來的產品組合影響。以有機口徑來看,調整後營運費用較前一年有利 4%,主要驅動因素是公司層級的一般及行政(G&A)費用下降。我們的調整後 EBITDA 為 8.32 億美元;以報表口徑下滑 3%,以固定匯率口徑下滑 5%,而以有機口徑(同樣已調整資產剝離)則成長 4%。本季約 27 億美元的 GAAP 淨損,部分原因是我們提前採用簡化商譽會計的新規則,導致約 22 億美元的商譽減損費用。

  • Let's get into our segment results. Starting on Slide 9 with the B + L international segment. Top level and all on an organic basis, revenue in the segment was up 2%, with solid contributions coming from Global Vision Care, up 9% and Global Surgical, up 4%. Global Consumer in our international pharma businesses were flat, and the Global Ophtho Rx business declined 3%. The organic growth in Global Vision Care in dollar terms was split evenly between the U.S., where we were up 16% versus Q1 '17 and outside the U.S., where we were up 6%.

    接著看各事業部門的結果。從第 9 張投影片開始,先看 B + L 國際事業部。以整體並且全部以有機口徑來看,該事業部營收成長 2%,其中全球視力保健(Global Vision Care)成長 9%、全球手術(Global Surgical)成長 4%,貢獻穩健。我們國際藥品業務中的全球消費者(Global Consumer)持平,而全球眼科處方藥(Global Ophtho Rx)業務下滑 3%。以金額來看,全球視力保健的有機成長在美國與美國以外各占一半:美國較 2017 年第一季成長 16%,美國以外成長 6%。

  • Beginning in late 2016, Joe took steps to globalize the lens business and to put in place leadership to drive this business forward. We started to see the results of those actions beginning in the second half of 2017, and that progress continued into Q1 of 2018. The progression over the last 4 quarters for the Global Vision Care business, beginning in Q2 of 2017, was minus 2% versus the prior year quarter, then plus 8%, plus 4% -- 5% and now plus 9% in the current quarter. All of those again are on an organic basis. Pretty good, right?

    自 2016 年底起,Joe 採取措施將隱形眼鏡業務全球化,並建立領導團隊以推動該業務向前。我們從 2017 年下半年開始看到這些行動的成果,而這股進展也延續到 2018 年第一季。全球視力保健業務在過去 4 個季度(自 2017 年第二季起)的走勢為:相較前一年同期為 -2%,接著 +8%、+4%--5%,而本季為 +9%。以上同樣皆為有機口徑。相當不錯,對吧?

  • During that period, both the international lens business under Yang Yang and the U.S. business under Joe Gordon delivered stronger results. The instauration of the U.S. Vision Care business has been particularly impressive. Starting in Q2 2017, the business declined 2% versus the same quarter in the prior year; then grew 10%; then grew 16%; and in the current quarter, grew 16%. The improvement has been driven by an increased promotional footprint; the launch of our Ultra Toric; the continued expansion of parameters on our other new products; and targeted use of price to drive meaningful increases in volume.

    在此期間,由 Yang Yang 領導的國際隱形眼鏡業務,以及由 Joe Gordon 領導的美國業務,都交出更強勁的成績。美國視力保健業務的復甦尤其令人印象深刻。自 2017 年第二季起,該業務相較前一年同期下滑 2%;接著成長 10%;再成長 16%;而本季成長 16%。改善的驅動因素包括:擴大促銷覆蓋範圍;推出 Ultra Toric;持續擴充我們其他新產品的規格參數;以及有針對性地運用價格策略,以帶動銷量的顯著提升。

  • Outside the U.S., our Asia Pacific region continues to be a source of attractive Vision Care growth, led by China, where our lens business was up 14% organically versus Q1 2017, as we continue to drive demand for both our newly launched and legacy products.

    在美國以外,亞太地區仍是視力保健成長的亮點來源,其中以中國為首;我們的隱形眼鏡業務相較 2017 年第一季有機成長 14%,因為我們持續推動新上市與既有產品的需求。

  • Global Surgical was up 4% organically as 7% growth in markets outside the United States more than offset a 3% year-over-year decline in the U.S. Outside the U.S., we continue to have success leveraging our strength in equipment, particularly Stellaris and the associated demand for our consumable products.

    全球手術業務有機成長 4%;美國以外市場成長 7%,足以抵銷美國市場年對年下滑 3%。在美國以外,我們持續成功運用我們在設備上的優勢,特別是 Stellaris,以及其帶動的耗材產品需求。

  • Global Consumer revenue was flat on an organic basis versus the prior year quarter, with the U.S. up 2% organically but offset by a decline outside the U.S. In the U.S., we had a sizable sell-in of product in Q4 of 2017 ahead of a seasonal promotional program with a large U.S. retailer, and the timing of that program dampened our U.S. Consumer sales in this quarter. Outside the U.S., the consumer business in China was up 20% organically, and Mexico was up 17% organically. But those gains were offset by a decline mainly in Russia due to a very weak cough/cold season and rebalancing of channel inventories. The international pharma business was also flat organically versus Q1 of '17 as strong growth in our Amoun operation was offset by declines in Russia and other Eastern European countries, again, mainly due to the rebalancing of channel inventories.

    全球消費者營收以有機口徑較前一年同期持平;其中美國有機成長 2%,但被美國以外的下滑所抵銷。在美國,我們在 2017 年第四季因應與一家大型美國零售商的季節性促銷方案而提前大量鋪貨(sell-in),而該方案的時點安排抑制了本季美國消費者銷售。在美國以外,中國的消費者業務有機成長 20%,墨西哥有機成長 17%。但這些增長被主要來自俄羅斯的下滑所抵銷,原因是咳嗽/感冒季節非常疲弱,以及通路庫存再平衡。國際藥品業務相較 2017 年第一季亦呈有機持平,因 Amoun 營運的強勁成長被俄羅斯及其他東歐國家的下滑所抵銷,同樣主要是通路庫存再平衡所致。

  • The Global Ophtho Rx business was down 3% organically as 6% growth outside the United States was more than offset by a 9% decline in the U.S. ophtho business. The decline in the U.S. was driven by a large low-margin sale of Visudyne in the prior year quarter. Full promotional activity against Vyzulta kicked off in January, and sales of Vyzulta in the quarter were nominal.

    全球眼科處方藥業務有機下滑 3%;美國以外成長 6%,但被美國眼科業務下滑 9% 所抵銷。美國的下滑主要是因前一年同期有一筆 Visudyne 的大型低毛利銷售。針對 Vyzulta 的完整推廣活動於 1 月啟動,而本季 Vyzulta 的銷售額仍屬有限。

  • Below revenue, I call your attention to the total operating expense line. On an organic basis, operating expenses were up or unfavorable by 2%. Mainly, this is reflective of us committing additional resources in selling, advertising and promotion, for example, resources in U.S. Consumer to support the launch of LUMIFY and the expanded deployment of [lens fifth sense] in the U.S. Vision Care business to sustain the recent volume in share gains there. We will continue to deploy resources to this important segment to deliver growth over the long term.

    在營收之下,我想請各位注意總營運費用這一行。以有機口徑來看,營運費用上升(或不利)2%。主要反映我們投入更多資源於銷售、廣告與促銷,例如在美國消費者業務投入資源以支援 LUMIFY 上市,以及在美國視力保健業務中擴大部署 [lens fifth sense],以維持近期在市占提升所帶來的銷量動能。我們將持續在這個重要事業部投入資源,以在長期實現成長。

  • Turning to Slide 10 and the results for the Branded Rx segment. Revenue was up 8% organically as we had a monster quarter in the largest component of this segment, Salix, plus growth in our dentistry and global Solta businesses that, together, more than offset the decline in our dermatology business. When looking at the 40% organic growth of Salix in the quarter, I'll dust off one of my favorite lines. The growth looks great, and we'll take it, but it's 1 quarter compared back to a quarter a year ago. Think back to Q1 of 2017 and recall that we were in a bit of disarray. While -- with the rumored sale of Salix, our loss of a large number of reps to a competitor and a significant contraction of both wholesale and retail pipeline inventories in Q1 of 2017. So attribute some of the growth this quarter to a weak Q1 '17.

    接著看第 10 張投影片與品牌處方藥(Branded Rx)事業部的結果。營收有機成長 8%,因為該事業部最大組成部分 Salix 本季表現非常亮眼,加上我們牙科與全球 Solta 業務的成長,合計足以抵銷皮膚科業務的下滑。談到 Salix 本季 40% 的有機成長,我要拿出我最常用的一句話。這樣的成長看起來很棒,我們也樂於接受,但這只是把 1 個季度拿來與一年前的同一季度相比。回想 2017 年第一季,當時我們的狀況有些混亂。當時—由於市場傳聞 Salix 可能出售、我們有大量業務代表流失到競爭對手,以及 2017 年第一季批發與零售管道庫存大幅收縮。因此,本季部分成長可歸因於 2017 年第一季基期偏弱。

  • Add to that a bit of increased realized selling prices in the current quarter and a favorable impact from better management of non-retail channels, and you get that 40% year-over-year growth. Obviously, this is above trend and expectations for the full year, but the takeaway should be that the hard work of the Salix team, led by Mark McKenna, has put Salix in a position to deliver fundamental growth across the portfolio of Rxs, of unit volumes and of realized selling prices. The Salix business is really firing on all cylinders.

    再加上本季已實現售價略有提升,以及透過更妥善管理非零售通路所帶來的有利影響,便促成了年增 40% 的成長。顯然,這高於全年趨勢與預期,但重點在於,由 Mark McKenna 領導的 Salix 團隊的辛勤努力,已使 Salix 具備在處方藥(Rx)產品組合、銷量與已實現售價等面向實現基本面成長的能力。Salix 業務確實是全面火力全開。

  • Our ortho dermatologic business continues in transition. We're doing our best to sustain our legacy product portfolio in a very challenging environment, while, at the same time, gearing up for the upcoming launches of the new innovative products that we believe will be the future of this business. In January, we expanded the dermatology sales force by approximately 25% to increase our efforts against SILIQ and Retin-A Micro 0.06% and to be fully deployed against potential high-volume prescribers well ahead of the expected launches of DUOBRII in the summer and ALTRENO and BRYHALI later in the year.

    我們的骨科皮膚科業務仍在轉型中。在極具挑戰的環境下,我們盡最大努力維持既有產品組合,同時也為即將上市、我們相信將成為此業務未來的新型創新產品做準備。1 月,我們將皮膚科銷售團隊擴編約 25%,以加大對 SILIQ 與 Retin-A Micro 0.06% 的推廣力道,並在預期於夏季上市的 DUOBRII 以及於今年稍晚上市的 ALTRENO 與 BRYHALI 之前,提前全面部署以鎖定潛在高處方量的醫師。

  • We now include Solta as part of the Branded Rx segment, and global Solta delivered 18% organic growth, with half coming from the U.S. and half outside the U.S. This is another business that benefited from a change in how it was organized and managed, including a change of leadership. A tip of the hat to Tom Appio, our Executive VP of International, for leading the changes that have transformed Solta into a global business with excellent future prospects.

    我們現在將 Solta 納入 Branded Rx(品牌處方藥)部門,而 Solta 全球業務實現 18% 的有機成長,其中一半來自美國、一半來自美國以外地區。這也是另一個受益於組織與管理方式調整(包括領導層變更)的業務。在此向我們的國際事業執行副總裁 Tom Appio 致敬,感謝他主導這些變革,使 Solta 轉型為具備優異未來前景的全球化業務。

  • Below the revenue line, I point out that operating expenses in the Branded Rx segment on an organic basis are up or unfavorable by 4%. Similar to my remarks about the B + L International segment, where appropriate, we're making in the -- investments in OpEx needed to support the future growth of this segment.

    在營收線以下,我要指出 Branded Rx 部門的營業費用(以有機基礎計)上升或不利增加 4%。與我對 B + L International 部門的評論類似,在適當之處,我們正在進行——為支持該部門未來成長所需的營業費用(OpEx)投資。

  • Turning to our diversified segment on Slide 11. Just a reminder, this is where the bulk of our LOE assets reside, as you can see on Slide 29 in the appendix. So it's expected to decline, but I'll point out that the rate of decline is slowing as we work our way through the massive LOE assets that are losing exclusivity over a relative short time frame. I do want to point out that we manage the assets in this segment to maximize the cash flow that can be generated from the portfolio, and our team, led by Barb Purcell, does a great job. If you look at Slide 35 in the appendix, just call your attention and notice the expansion of our sales force and promotional efforts around Wellbutrin and Aplenzin, which are reinvigorating those brands.

    接著看第 11 頁投影片的多元化部門。提醒一下,如附錄第 29 頁投影片所示,我們大部分的 LOE 資產都在這裡。因此預期會下滑,但我要指出,隨著我們逐步度過在相對短時間內大量失去獨占性的重大 LOE 資產,下滑速度正在放緩。我也要強調,我們管理此部門資產的目標是將該產品組合可產生的現金流最大化,而由 Barb Purcell 領導的團隊做得非常出色。如果你看附錄第 35 頁投影片,請特別注意我們在 Wellbutrin 與 Aplenzin 周邊擴大銷售團隊與推廣活動,正讓這些品牌重新煥發活力。

  • I'm going to switch gears and turn to the balance sheet summary on Slide 12. We ended the quarter just -- with just north of $900 million of cash on hand and $25.6 billion of debt. You could see the progress we made in reducing our debt, and we are in the process of repaying an additional $150 million of senior notes due 2020, which is a good segue to Slide 13, a slide you've seen before but one that is important in measuring our efforts not just to reduce debt but to manage our upcoming maturities as well.

    我將轉換話題,來看第 12 頁投影片的資產負債表摘要。本季結束時,我們手上現金略高於 9 億美元,負債為 256 億美元。你可以看到我們在降低負債方面取得的進展;我們也正在償還 2020 年到期的 1.5 億美元優先票據,這也順勢帶到第 13 頁投影片——你之前看過,但它對衡量我們不僅降低負債、也管理即將到期債務的努力非常重要。

  • Since last November, we reduced the amount of debt due in 2020 from $4.4 billion to $2.7 billion as of February 28 to the $1.078 billion you see as of May 8. Although 2020 and 2021 seem a long way off, we're focused on staying ahead of the future maturities and ensuring that the company maintains access to the capital markets to manage its liabilities. I've said this before, but I think it bears repeating, our efforts in 2017 and through today have provided us with a clear pathway, including a range of options to deal with our debt load. Good progress but plenty more work to be done for sure.

    自去年 11 月以來,截至 2 月 28 日,我們將 2020 年到期的債務金額從 44 億美元降至 27 億美元;而截至 5 月 8 日,已降至你所看到的 10.78 億美元。雖然 2020 與 2021 看似還很遠,但我們專注於提前因應未來到期債務,並確保公司維持進入資本市場的能力,以管理其負債。我以前說過,但我認為值得重申:我們在 2017 年以及至今的努力,已為我們提供一條清晰路徑,包含一系列可用選項來處理我們的負債水位。進展良好,但毫無疑問仍有大量工作要做。

  • On to Slide 14 and the cash flow summary. Here, I just want to point out that, after we provided 2018 guidance, we indicated that the smooth average of expected cash provided by operating activities might be in the low $400 millions per quarter. Q1 of 2018 was a strong cash flow quarter as we generated $438 million, despite paying $170 million of legacy legal settlements in the quarter. Good stuff, indeed.

    接著看第 14 頁投影片的現金流摘要。在這裡我只想指出,在我們提供 2018 年指引之後,我們曾表示營運活動所提供的預期現金流平滑平均值,可能每季約在 4 億美元出頭。2018 年第一季是現金流強勁的一季,我們產生了 4.38 億美元,儘管該季支付了 1.7 億美元的歷史法律和解金。確實是好消息。

  • On to the updated guidance slide on Slide 15. The headlines are that we increased our revenue guidance range by $50 million and our adjusted EBITDA range by $100 million. There are what I will call modest changes in some of our key assumptions, and those that changed are shown in red on the slide.

    接著看第 15 頁投影片的更新指引。重點是:我們將營收指引區間上調 5,000 萬美元,並將調整後 EBITDA 指引區間上調 1 億美元。我們對部分關鍵假設做了我稱之為「小幅」的調整,變動的項目在投影片上以紅色標示。

  • Turn to Slide 16, the bridge for our -- from our prior guidance to our updated guidance. But for the unfavorable movement in FX rates, our expectations for revenue increased by $120 million, comprised of $25 million in our LOE portfolio and, importantly, that's coming not from a change in the expected timing of the LOEs but from better fundamental performance; next, $55 million from stronger expected performance of APRISO, Uceris and Zegerid; and finally, $40 million in improved outlook, of course, our -- across our other core businesses. On the adjusted EBITDA bridge, the $10 million negative impact from FX includes the favorable $25 million FX gain on the intercompany loans included in our Q1 '18 results, but that pickup was more than offset by the estimated translational impact of unfavorable movements in FX rates from February to this forecast and the FX loss on intercompany loans so far in Q2.

    請看第 16 頁投影片,這是從先前指引到更新指引的——銜接橋。若非匯率(FX)變動不利,我們對營收的預期將增加 1.2 億美元,其中包括 LOE 產品組合的 2,500 萬美元;而且重要的是,這並非來自 LOE 發生時間點預期的改變,而是來自更佳的基本面表現;其次,APRISO、Uceris 與 Zegerid 的預期表現更強,帶來 5,500 萬美元;最後,其他核心業務的展望改善,帶來 4,000 萬美元。在調整後 EBITDA 的橋接中,匯率造成的 1,000 萬美元負面影響,包含我們 2018 年第一季結果中公司間貸款帶來的 2,500 萬美元匯兌收益,但該收益被自 2 月至本次預測期間匯率不利變動的預估換算影響,以及第二季迄今公司間貸款的匯兌損失所抵銷且有餘。

  • In my opinion, the most important takeaway from quarterly results is how those results inform your view of our future prospects. Our results in Q1 2018 provided the support to raise our guidance for the year, and that's a good thing.

    我認為,季度業績最重要的重點在於,這些結果如何影響你對我們未來前景的看法。我們在 2018 年第一季的結果,支持我們上調全年指引,這是件好事。

  • Back to you, Joe.

    交給你了,Joe。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Thank you, Paul. Let's start with an update on the Bausch + Lomb/International segment on Slide #17. Overall, this segment delivered organic growth of 2% versus Q1 '17, driven by strong growth in Global Vision Care and Global Surgical. The China portfolio was particularly strong, with 15% organic growth compared to last year's first quarter.

    謝謝你,Paul。我們先從第 #17 頁投影片的 Bausch + Lomb/國際部門更新開始。整體而言,該部門相較 2017 年第一季實現 2% 的有機成長,主要由全球視力保健與全球手術業務的強勁成長所帶動。中國產品組合表現尤其強勁,與去年第一季相比有機成長 15%。

  • The chart on the right shows the U.S. contact lens manufacturer growth as compared to a year ago. Bausch + Lomb is significantly outperforming the competitors' growth rate. This is another great example of successful execution as the investments we made into growth capital and new products to support this business are now translating into strong growth. In addition, we continue to expand on ULTRA, and we've recently received FDA approval for an extended wear indication.

    右側圖表顯示美國隱形眼鏡製造商相較一年前的成長情況。Bausch + Lomb 的表現明顯優於競爭對手的成長率。這是成功執行的另一個絕佳例子:我們先前在成長資本與新產品上的投資以支持此業務,如今正轉化為強勁成長。此外,我們持續擴展 ULTRA,且近期已獲得 FDA 對延長配戴適應症的核准。

  • In the consumer business, we delivered industry-leading growth in consumption, up 4.3% across all products in the first quarter of 2018. This growth was led by more than 20% growth in the PreserVision and Soothe franchises, while the overall U.S. health and beauty retail category was actually down 8.8%. Our e-commerce presence also continues to grow, with Amazon sales up 44% compared to the first quarter of 2017. And we continue to advance innovative new products in this segment, including 3 of the significant 7 new products, VYZULTA for glaucoma, LUMIFY for ocular redness and Si-Hy Daily lenses, which are expected in the fourth quarter.

    在消費者業務方面,我們在2018年第一季於所有產品的消費量實現業界領先的成長,整體上升4.3%。此成長主要由PreserVision與Soothe系列超過20%的成長所帶動,而美國整體健康與美容零售品類實際上下降了8.8%。我們的電商布局也持續擴大,與2017年第一季相比,Amazon銷售額成長44%。我們也持續在此領域推進創新新品,包括7項重要新品中的3項:用於青光眼的VYZULTA、用於眼部發紅的LUMIFY,以及預計於第四季推出的Si-Hy Daily隱形眼鏡。

  • Finally, we have submitted to the FDA loteprednol gel, 0.38% for ocular inflammation during the second quarter of 2018. This new formulation has improved dissolution kinetics, improved penetration into the eye and reduced concentration of dosage with a similar efficacy profile. As a result, we believe this life cycle product enhancement will be preferred by patients and physicians.

    最後,我們已於2018年第二季向FDA提交loteprednol凝膠0.38%,用於治療眼部發炎。此新配方具有更佳的溶解動力學、提升進入眼內的滲透性,並在療效相近的情況下降低給藥濃度。因此,我們相信這項生命週期產品強化將更受患者與醫師青睞。

  • Going back to LUMIFY for a moment. Let's move to Slide #18. LUMIFY is the first and only over-the-counter eye drop with low-dose brimonidine for the treatment of ocular redness. Ocular redness is a common condition that can be caused by inflammation of almost any part of the eye. When this condition is treated frequently with nonselective redness-relieving eye drop, users can develop tolerance or experience a loss of effectiveness as well as rebound redness. But the active ingredient in LUMIFY, low-dose brimonidine, selectively constricts the veins in the eye, which increases the availability of oxygen to surrounding tissues and reduces the potential risk of these side effects.

    回到LUMIFY再談一下。我們來看第18頁投影片。LUMIFY是第一個也是唯一一個含低劑量brimonidine、用於治療眼部發紅的非處方(OTC)眼藥水。眼部發紅是一種常見狀況,幾乎眼睛任何部位的發炎都可能引起。若經常使用非選擇性的消紅眼藥水治療,使用者可能產生耐受性或感到效果下降,並可能出現反彈性發紅。但LUMIFY的有效成分低劑量brimonidine可選擇性地收縮眼部靜脈,提升周邊組織的氧氣可用性,並降低上述副作用的潛在風險。

  • We announced yesterday that LUMIFY is now shipping and will be in stores later this month. In addition to the rechannel, our prescription ophtho sales force will be sampling this OTC product with doctors, as we have done successfully for with other consumer products like PreserVision. We expect that physician recommendations will translate into retail demand.

    我們昨天宣布,LUMIFY目前已開始出貨,並將於本月稍晚在門市上架。除了通路重新配置之外,我們的處方眼科銷售團隊也將與醫師合作提供此OTC產品的試用裝,就像我們先前對PreserVision等其他消費者產品所成功採行的做法。我們預期醫師推薦將轉化為零售端需求。

  • Turning now to Slide 19, the headline on the Salix business that we delivered growth across the entire portfolio of promoted products in the first quarter. Revenue growth of 40% in the quarter was driven by improved operational effectiveness and an investment we made in our sales force more than a year ago. The chart on the top right shows the success we've had in growing this business since the Salix acquisition in 2015, with net revenues tracking more than 10% annual growth since the acquisition.

    接著看第19頁投影片,Salix業務的重點是:我們在第一季於整個推廣產品組合全面實現成長。本季40%的營收成長,主要來自營運效能的提升,以及我們在一年多前對銷售團隊所做的投資。右上方圖表顯示,自2015年收購Salix以來,我們成功推動該業務成長;自收購後,淨營收的走勢一直維持每年超過10%的成長。

  • XIFAXAN and RELISTOR led the way in revenue growth, up 49% and 54%, respectively, compared to the first quarter of 2017. The chart on the bottom right shows RELISTOR's total prescriptions up 44% in the first 13 weeks of 2018 versus the prior year. APRISO and UCERIS also delivered strong revenue growth in the first quarter, up 31% and 27%, respectively, compared to quarter 1 2017. On the pipeline front, we announced yesterday, PLENVU, our next-generation bowel-cleansing preparation for colonoscopy, was approved ahead of the scheduled date -- PDUFA date.

    XIFAXAN與RELISTOR帶動營收成長,與2017年第一季相比,分別成長49%與54%。右下方圖表顯示,2018年前13週RELISTOR的總處方量較去年同期成長44%。APRISO與UCERIS在第一季也交出強勁的營收成長,與2017年第一季相比,分別成長31%與27%。在研發管線方面,我們昨天宣布,用於大腸鏡檢查的次世代腸道清潔製劑PLENVU已提前於原定日期——PDUFA日期——獲得核准。

  • When it came to Valeant, there were several areas that needed more focus, and candidly, one of those areas was Salix. So we brought Mark McKenna over from the Bausch + Lomb team, where he was Vice President and General Manager. Mark looked at the pieces of the Salix business and identified areas that needed improvement. For example, we had high turnover in the sales force. We had a new XIFAXAN indication for IBS-D, but we weren't calling on the Primary Care physicians. With new leadership in place, we were able to address the turnover issue and build a Primary Care sales force. Now having made the investments we needed to make, the business is growing nicely, and XIFAXAN is driving a substantial amount of that growth, including a higher refill compliance rate with hepatic encephalopathy patients.

    談到Valeant時,有幾個領域需要更聚焦;坦白說,其中之一就是Salix。因此我們從Bausch + Lomb團隊調任Mark McKenna過來,他當時擔任副總裁兼總經理。Mark檢視了Salix業務的各個環節,並找出需要改善的領域。例如,我們的銷售團隊流動率很高。我們雖然取得XIFAXAN針對IBS-D的新適應症,但我們並未拜訪基層醫療(Primary Care)醫師。在新領導到位後,我們得以解決流動率問題,並建立基層醫療銷售團隊。如今在完成必要投資後,業務成長良好,而XIFAXAN正驅動其中相當大部分的成長,包括在肝性腦病變患者中更高的續配合規率。

  • I'm going to ask Mark, who is here with us today, to take us through the next slide for more of an update on XIFAXAN. Mark?

    我想請今天也在現場的Mark,帶我們看下一頁投影片,提供更多關於XIFAXAN的最新進展。Mark?

  • Mark McKenna - Senior VP & GM

    Mark McKenna - Senior VP & GM

  • Thank you, Joe, for inviting me on the call and for your comments. The team shares your enthusiasm about XIFAXAN's potential.

    謝謝你,Joe,邀請我參與這通電話會議,也謝謝你的評論。團隊也和你一樣,對XIFAXAN的潛力感到振奮。

  • In XIFAXAN, we have the first and the only approved microbiome drug for IBS-D. This is a significant differentiator that offers patients a short-term treatment with long-lasting relief. As you know, we announced in the last quarter's call that XIFAXAN had reached blockbuster status during the first quarter of 2018. It is a significant milestone that a lot of people in this office helped achieve. And the momentum continues. Just last week, XIFAXAN hit an all-time prescription high.

    就XIFAXAN而言,我們擁有第一個也是唯一一個獲核准用於IBS-D的微生物組藥物。這是一項重要的差異化優勢,能為患者提供短期療程、但具長效緩解的治療選擇。如各位所知,我們在上一季的電話會議中宣布,XIFAXAN在2018年第一季達到重磅藥(blockbuster)地位。這是一個重要里程碑,辦公室裡許多人都為此付出並促成達成。而這股動能仍在延續。就在上週,XIFAXAN的處方量創下歷史新高。

  • With that in mind, I want to dive into XIFAXAN's first quarter performance. If you look at the chart on the right, you can see XIFAXAN prescriptions were up 7% year-over-year during the first 13 weeks of 2018, driven by the Primary Care sales force investment that you just talked about, Joe and continued growth in our GI segment as well as proactive steps we took, including adjusting our copay offers to improve refill rates during the high-deductible season.

    基於此,我想深入說明XIFAXAN第一季的表現。如果你看右側圖表,可以看到2018年前13週XIFAXAN處方量年增7%;成長動能來自你剛提到的、我們對基層醫療銷售團隊的投資(Joe),以及我們在腸胃科(GI)領域的持續成長,還有我們採取的主動措施,包括在高自付額季節調整自付額(copay)優惠,以提升續配率。

  • During the quarter, we increased NRx market share from 77% to 81%, with the bulk of the growth coming from IBS-D. In fact, the chart on the bottom right shows that NRx market share is up 20 points in Primary Care as a result of the sales force expansion we implemented in February of 2017. We believe we are just scratching the surface on this opportunity.

    本季期間,我們將NRx市占率從77%提升至81%,其中大部分成長來自IBS-D。事實上,右下方圖表顯示,由於我們在2017年2月實施的銷售團隊擴編,基層醫療端的NRx市占率提升了20個百分點。我們相信這個機會才剛開始被開發。

  • So what's next for XIFAXAN? We believe we have a durable asset, and we will continue to invest in this product through the study of new indications and new formulations of rifaximin. We've initiated the enrollment of clinical sites in a 300-plus-patient Phase II clinical study for the treatment of acute overt hepatic encephalopathy. The data gained from this trial will allow us to study the new rifaximin formulation in a number of additional indications in gastrointestinal and liver diseases. We are planning to initiate a second study in -- with SIBO later this year. As you may be aware, there are no approved products for small intestinal bacterial overgrowth.

    那麼XIFAXAN接下來的重點是什麼?我們認為這是一項具持久性的資產,並將透過研究rifaximin的新適應症與新劑型,持續投資此產品。我們已在一項超過300名患者的第二期臨床試驗中啟動臨床中心收案,用於治療急性顯性肝性腦病變。此試驗取得的數據將使我們能在多項腸胃道與肝臟疾病的其他適應症中,研究新的rifaximin劑型。我們計畫於今年稍晚啟動第二項針對SIBO的研究。如各位可能知道,目前尚無針對小腸細菌過度生長的核准產品。

  • To wrap up, XIFAXAN is a solid growth driver. We are taking concrete steps to build this franchise for the future.

    總結來說,XIFAXAN 是強勁的成長驅動力。我們正採取具體措施,為未來打造這項事業版圖。

  • Joe, I'll turn it back to you.

    Joe,我把時間交還給你。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Thank you, Mark. As you can you hear, Mark's done a great job with Salix.

    謝謝你,Mark。如各位所聽到的,Mark 在 Salix 的工作做得非常出色。

  • Let's turn to Slide #21 for Ortho Dermatologics update. Our focus in dermatology has been on building and advancing a pipeline of new products. We have made a lot of progress in this area over the last quarter.

    接著我們看第 21 張投影片,更新 Ortho Dermatologics 的進展。我們在皮膚科領域的重點一直放在建立並推進新產品的研發管線。在上一季,我們在這方面取得了很大進展。

  • First, we expanded the SILIQ launch after successfully executing the REMS certification of more than 2,500 doctors. What we found through this process that -- was SILIQ's status as the first and only IL-17 blocker really resonates with physicians who are impressed with the fast response in a high percentage of patients who are reaching complete skin clearance levels. Second, we launched a new strength of Retin-A Micro, 0.06%, in January. Sales of the 0.06% formulation are tracking above expectations, and as the chart in the right shows, we also seeing continued strength in the 0.08% formulation.

    首先,在成功完成超過 2,500 位醫師的 REMS 認證後,我們擴大了 SILIQ 的上市推廣。我們在此過程中發現,SILIQ 作為第一且唯一的 IL-17 阻斷劑,其定位確實引起醫師強烈共鳴;醫師對於相當高比例患者能快速反應、並達到完全皮膚清除程度的表現印象深刻。第二,我們於 1 月推出了 Retin-A Micro 的新濃度 0.06%。0.06% 劑型的銷售表現高於預期;且如右側圖表所示,0.08% 劑型也持續展現強勁動能。

  • Let's stay on derm as we move to Slide #22 for a deeper dive on how we expect to double the revenue of the dermatology business in the next 5 years. Here, you can see our very active dermatology pipeline and the new products we have recently launched and anticipate launching in the near future. Starting on the left. We have the 2017 base business plus SILIQ. Building on that for 2018, I should point out these boxes are not drawn to scale, we add Retin-A Micro 0.06%, which was launched in January; DUOBRII for psoriasis with a PDUFA date coming up next month; ALTRENO, an acne treatment with a PDUFA date on August 27; and finally, BRYHALI for psoriasis with an October 5 PDUFA date.

    我們繼續聚焦皮膚科,前往第 22 張投影片,更深入說明我們預期如何在未來 5 年將皮膚科業務營收翻倍。在這裡,各位可以看到我們非常活躍的皮膚科研發管線,以及我們近期已上市、並預期在不久的將來推出的新產品。從左邊開始。我們有 2017 年的基礎業務加上 SILIQ。在此基礎上展望 2018 年,我要指出這些方塊並非按比例繪製;我們新增 1 月上市的 Retin-A Micro 0.06%;用於乾癬的 DUOBRII,其 PDUFA 日期在下個月;治療痤瘡的 ALTRENO,其 PDUFA 日期為 8 月 27 日;最後是用於乾癬的 BRYHALI,其 PDUFA 日期為 10 月 5 日。

  • We add to that our additional pipeline candidates for acne and atopic dermatitis that we believe show a lot of promise for 2020 to 2022 time frame. To highlight one, IDP-120 is a topical treatment for acne that contains a fixed-dose combination of tretinoin and benzoyl peroxide gel. We have completed Phase II studies for IDP-120, and the Phase III studies are expected to begin in the second half of 2018.

    此外,我們還有針對痤瘡與異位性皮膚炎的其他研發管線候選產品,我們相信在 2020 至 2022 年期間將展現很大潛力。舉其中一項為例,IDP-120 是一種治療痤瘡的外用藥,含有固定劑量複方的維 A 酸(tretinoin)與過氧化苯甲醯(benzoyl peroxide)凝膠。我們已完成 IDP-120 的第二期研究,預計第三期研究將於 2018 年下半年開始。

  • So this gives you a sense of both the near- and longer-term business horizon for the product launches we are preparing for and anticipating in the Ortho Dermatologics business. Our team is working hard to create a path that enables us to double the revenue of this business over the next 5 years. A special thank you to our entire R and (sic) [R&D] team, especially our derm R&D team.

    因此,這讓各位對我們在 Ortho Dermatologics 業務中,正在準備與預期推出的產品上市計畫之近期與中長期展望都有所了解。我們的團隊正努力打造一條路徑,使我們能在未來 5 年將此業務的營收翻倍。特別感謝我們整個 R and(原文如此)[R&D] 團隊,尤其是我們的皮膚科研發團隊。

  • If we go to the next slide, Slide 23. It represents the results of what I call as going shopping in our own closet, which means looking for existing products and businesses with untapped potential. The first example I want to highlight is the global Solta aesthetics business. This business, which we have announced, will be reported as part of our Ortho Dermatologics going forward, delivered an 18% organic revenue growth in the first quarter of the year. This performance is the result of a global expansion of the existing portfolio of promoted products in Asia Pacific, Europe and the Middle East.

    如果我們看下一張投影片,第 23 張。它呈現了我所稱的「在自家衣櫥裡逛街」的成果,也就是尋找現有產品與業務中尚未被充分發掘的潛力。我想首先強調的例子是 Solta 的全球醫美業務。我們已宣布,該業務未來將納入 Ortho Dermatologics 進行揭露;其在今年第一季實現了 18% 的有機營收成長。這項表現來自於在亞太、歐洲與中東地區,對既有主推產品組合進行全球擴張。

  • We also have 2 current branded products in the Neuro & Other portfolio that had benefited from our brand refocus and promotional restart. Specifically, we have expanded the sales team for Wellbutrin XL and initiated a telesales program that is working very well. Revenue was up 23% in the quarter versus last year. Migranal TRxs are up 29% in the first 13 work -- weeks of 2018 after we restarted sales promotion, initiated a new message platform and expanded telesales program. So to wrap up, I think this slide demonstrates very clearly the investments we are making are paying off and generating growth for our shareholders.

    此外,在 Neuro & Other 產品組合中,我們也有 2 項現有品牌產品受惠於品牌重新聚焦與促銷重啟。具體而言,我們擴編了 Wellbutrin XL 的銷售團隊,並啟動了一項運作成效非常好的電話銷售(telesales)計畫。本季營收較去年同期成長 23%。在我們重啟銷售推廣、啟用新的訊息平台並擴大電話銷售計畫後,Migranal 的 TRx 在 2018 年前 13 個工作週成長 29%。因此總結來說,我認為這張投影片非常清楚地顯示,我們所做的投資正在見效,並為股東帶來成長。

  • Let's move on to Slide #24. Here, we put a timeline out for the significant set of products that we expect to generate $1 billion in peak sales collectively within 5 years. As you can see, 4 of the 7 products have now launched, with LUMIFY shipping yesterday. Two products have PDUFA dates coming up later this year, and we are preparing to launch a silicone hydrogel daily in select regions in the fourth quarter. These 7 innovative and diversified products span the entire therapeutic areas in which we are focused, including eye care, GI and dermatology.

    接著我們看第 24 張投影片。在這裡,我們列出一條時間軸,涵蓋我們預期在 5 年內合計可創造 10 億美元峰值銷售額的一組重要產品。如各位所見,7 項產品中已有 4 項上市,其中 LUMIFY 昨天已開始出貨。另有 2 項產品的 PDUFA 日期將在今年稍晚到來,而我們也正準備在第四季於部分地區推出矽水膠日拋產品。這 7 項具創新性且多元化的產品,涵蓋我們聚焦的所有治療領域,包括眼科照護、腸胃道(GI)與皮膚科。

  • As I said when I joined Valeant, innovation will be a key factor in this company's transformation, and that is why R&D has been an area of investment for this team. For those who want more detail on our later-phase pipeline, we have provided Slide #30 in the appendix that lays out recent and upcoming product launches and near-term PDUFA dates for the innovative products we are developing.

    正如我加入 Valeant 時所說,創新將是公司轉型的關鍵因素,因此研發一直是本團隊的投資重點之一。對於希望更了解我們後期研發管線的人,我們在附錄提供了第 30 張投影片,列出我們正在開發的創新產品之近期與即將到來的上市計畫,以及短期內的 PDUFA 日期。

  • On Slide 25, we review the 2018 commitments and expected targets we outlined at the beginning of the year. These 5 areas of focus remain the foundation of our plan to drive growth and shareholder value.

    在第 25 張投影片中,我們回顧年初所提出的 2018 年承諾與預期目標。這 5 個重點領域仍是我們推動成長與股東價值計畫的基石。

  • Before we conclude, I want to turn to Slide #26 and take a minute to talk about another important announcement we made this morning. Beginning in July of this year, this company will be known as Bausch Health Companies. This decision was considered carefully by our board and management team over a long period of time. We looked at a number of available options and determined that the name Bausch Health Companies most accurately represents the full scope of our portfolio, which includes not only pharmaceutical but medical devices and over-the-counter consumer health products. The new name also builds on a legacy that supports our mission to improve people's lives with our health care products. In my view, Bausch Health Companies perfectly reflects the company we are today: innovative, global and focused on patients' health. Importantly, I want to emphasize that this change is happening at the corporate level, so the B + L or Bausch + Lomb, Salix and Ortho Dermatologics businesses will continue to use their existing names and brands in the United States and around the world. And outside the U.S., our subsidiaries and businesses with separate established brand names will continue to operate under their existing names.

    在結束之前,我想轉到第 26 張投影片,用一點時間談談我們今天早上發布的另一項重要公告。自今年 7 月起,本公司將更名為 Bausch Health Companies。這項決定經董事會與管理團隊長時間審慎評估。我們檢視了多種可行選項,並認定「Bausch Health Companies」最能準確代表我們產品組合的完整範疇,其中不僅包含藥品,也包含醫療器材與非處方(OTC)消費者健康產品。新名稱也延續一項傳承,支持我們以醫療保健產品改善人們生活的使命。在我看來,Bausch Health Companies 完美反映了我們今日的公司樣貌:創新、全球化,並以病患健康為核心。重要的是,我要強調這項變更發生在公司層級,因此 B + L 或 Bausch + Lomb、Salix 與 Ortho Dermatologics 事業在美國及全球仍將沿用其既有名稱與品牌。而在美國以外,我們具有各自既有品牌名稱的子公司與業務也將持續以原名稱營運。

  • Along with this change, we will trade under the BHC ticker, and we'll be rolling out a new branded entity logo and website in the coming months. And to provide our shareholders with greater transparency, we will start in quarter 2 2018 to report and operate in 4 reporting segments: Bausch + Lomb/International, Salix, Ortho Dermatologicly (sic) [Dermatologics] and our Diversified Products. I'm excited about this development because it signals that we have reached an important point in the turnaround process, where the steps we have taken are yielding concrete results, and we're beginning to turn the page away from legacy issues that have been headwinds over the past few years.

    配合這項變更,我們將以 BHC 代號交易,並將在未來幾個月推出新的品牌實體標誌與網站。此外,為了讓股東獲得更高透明度,我們將自 2018 年第二季起,以 4 個報導分部進行揭露與營運:Bausch + Lomb/International、Salix、Ortho Dermatologicly(原文如此)[Dermatologics] 以及我們的 Diversified Products。我對這項進展感到振奮,因為它顯示我們已在轉型過程中到達一個重要節點:我們採取的措施正在產生具體成果,而我們也開始翻過過去幾年造成阻力的歷史遺留問題這一頁。

  • With that, operator, let's open up the line for any questions.

    那麼,接線員,讓我們開放電話線供大家提問。

  • Operator

    Operator

  • Your first question comes from the line of Annabel Samimy with Stifel.

    第一個問題來自 Stifel 的 Annabel Samimy。

  • Annabel Eva Samimy - MD

    Annabel Eva Samimy - MD

  • So I just need to ask you about the dermatology portfolio. In a year's time, you will have essentially completely refreshed this dermatology portfolio. Outside of the expansion of the sales force, are there any commercial plans for sort of bringing these products to gain -- or bundling these products to gain some kind of preferential positioning with payers? Or any commercial strategies at all to really expose your dominance in this medical dermatology area? And then on SILIQ, I know that you've been in a softer launch, focusing on REMS certification. Are we now in that stage where this -- you're going to have a much stronger presence from a DTC effort to really broaden to a larger audience now that you also have -- are going to have a bigger portfolio with that?

    我想請教一下皮膚科產品組合。在一年之內,你們基本上會把這個皮膚科產品組合幾乎完全更新一遍。除了擴編銷售團隊之外,在商業面是否有任何計畫,例如讓這些產品更容易取得——或將這些產品打包,以便在與付款方(payers)的談判中取得某種優先地位?或是有任何商業策略,能真正凸顯你們在醫學皮膚科領域的主導地位?另外關於 SILIQ,我知道你們一直採取較溫和的上市策略,重點放在 REMS 認證。那我們現在是否已進入下一階段——也就是在你們同時也將擁有更大的產品組合之後,會透過 DTC(直接面向消費者)推廣,讓市場能見度大幅提升、觸及更廣泛受眾?

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • So a couple of good questions. And let me say -- dermatology, we are very excited about the opportunity to double the dermatology business, but, candidly, we've acknowledged that the dermatology turnaround is approximately 12 months behind the rest of the Valeant turnaround. What did we do? We clearly had to bring in new leadership. That new leadership came in last January, and that was clearly one of the important things that we needed to do. The second thing that we needed to do is, realizing that we had some significant new product launches, what we invested in was a new sales force. We increased the number of sales reps in our total sales organization and, importantly, reallocated them so that we now have a complete psoriasis team of sales representatives to go to market to help us, especially with SILIQ but then also with DUOBRII and BRYHALI as the new products that are coming. So that really is the primary way in which we believe that we will turn this business around. As I said, going back last 6 months, it's all going to come down to dermatology and the launch of our new products. These -- we have 5 new products to launch, starting with SILIQ that we launched last year, moving to the RAM -- or Retin-A Micro 0.06%, going to DUOBRII, ALTRENO and BRYHALI. It is those 5 new products that is really going to be the stimulus for the growth in going forward into the marketplace, coupled with the incremental sales organization. It's very similar to what we did with Salix. We added sales representatives in Salix, and now we're experiencing the benefit of that in 2018. In January, we added sales representatives. I expect, a year from now, as we're talking about these new launches and talking about the sales organization, that, you'll see, is really going to be what's going to drive our dermatology business under the leadership of Bill Humphries, our new leader there. So that's really the primary area in which we will compete. We've already had some very important discussions with managed care market access about a product like DUOBRII that we think is a potential game changer. And the reason I say that, if we can help patients to avoid the need for a biologic and the cost of a biologic and delay that for 6 months or something like that, we think that's obviously going to save managed care and employers significant value but still give patients what they're looking for, a topical treatment for psoriasis. So look to us to have more to say about the DUOBRII launch in the next several months as we approach that PDUFA date. But it's going to come down to investment in a new leadership, new sales force and new products is really going to be the key for our dermatology business.

    這是幾個很好的問題。我先說——皮膚科方面,我們對於把皮膚科業務規模翻倍的機會感到非常興奮,但坦白說,我們也承認皮膚科的扭轉進度大約比 Valeant 其他業務的扭轉晚了約 12 個月。我們做了什麼?很明顯,我們必須引進新的領導團隊。新的領導團隊在去年一月到位,這顯然是我們必須做的關鍵事項之一。第二件我們需要做的事是,意識到我們有幾個重要的新產品即將上市,因此我們投資建立了一支新的銷售團隊。我們增加了整體銷售組織的業務代表人數,更重要的是重新配置資源,因此我們現在擁有一支完整的乾癬銷售代表團隊來推向市場,協助我們,特別是針對 SILIQ,同時也為即將推出的新產品 DUOBRII 與 BRYHALI 做準備。因此,我們認為這確實是扭轉這項業務的主要方式。如我所說,回顧過去 6 個月,一切都將取決於皮膚科以及我們新產品的上市表現。我們——將有 5 個新產品要上市,從去年已上市的 SILIQ 開始,接著是 RAM——也就是 Retin-A Micro 0.06%,再到 DUOBRII、ALTRENO 以及 BRYHALI。這 5 個新產品將真正成為未來推動市場成長的刺激因素,再加上新增的銷售組織投入。這與我們在 Salix 所做的非常類似。我們在 Salix 增加了銷售代表,而我們在 2018 年正開始看到其效益。我們在一月增加了銷售代表。我預期一年後,當我們談論這些新上市產品並談論銷售組織時,你會看到這將真正成為在 Bill Humphries(我們那邊的新領導)帶領下推動皮膚科業務的動力。因此,這確實是我們競爭的主要領域。我們已經就像 DUOBRII 這樣的產品,與受管理式醫療(managed care)的市場准入團隊進行了一些非常重要的討論,我們認為它可能會改變遊戲規則。我之所以這麼說,是因為如果我們能幫助病人避免使用生物製劑的需求、避免生物製劑的成本,並將其延後 6 個月之類的時間,我們認為這顯然能為受管理式醫療與雇主節省可觀的價值,同時仍能提供病人所尋求的——用於乾癬的外用治療。因此,隨著我們接近該 PDUFA 日期,未來幾個月請期待我們就 DUOBRII 的上市會有更多說明。但歸根結底,投資新的領導團隊、新的銷售團隊以及新產品,將是我們皮膚科業務的關鍵。

  • Operator

    Operator

  • Your next question comes from the line of Umer Raffat with Evercore.

    下一個問題來自 Evercore 的 Umer Raffat。

  • Umer Raffat - Senior MD & Fundamental Research Analyst

    Umer Raffat - Senior MD & Fundamental Research Analyst

  • I have a few, if I may, and maybe just, Joe, for you and for Paul. I'm a little confused about the FX reported this quarter because, for all the other companies we look at in large-cap biopharma, they all had a headwind from FX. And the way the comparison tables are laid out, it makes it look like FX was a tailwind in your numbers. So I'm just curious why that is and maybe just to get some color there. On Salix, I wanted to understand what the revision of contractual term implies and if you could quantify that for us. And will that continue [with] the balance of the year? And then finally, I want to focus on your Slide 42, which is a channel inventory. That slide implies that GI inventories are actually down from 1Q '17 to 1Q '18, but as you discussed in opening remarks, inventories have actually improved. So my question is, what exactly does that disclosure imply? And I ask because of -- because investors have really cared about this disclosure in the past because of some of the legacy Salix issues.

    如果可以的話我有幾個問題,也許是給 Joe 以及 Paul。我對本季所報告的外匯(FX)影響有點困惑,因為就我們觀察的其他大型生物製藥公司而言,外匯對它們都是逆風。而從你們的比較表呈現方式來看,似乎外匯在你們的數字中反而是順風。所以我想了解為什麼會這樣,也希望能多給一些背景說明。關於 Salix,我想了解合約條款(contractual term)的修訂意味著什麼,以及你們是否能為我們量化其影響。而這種情況會在今年剩餘期間持續嗎?最後,我想聚焦在你們的第 42 張投影片,也就是通路庫存(channel inventory)。那張投影片顯示 GI 的庫存其實從 2017 年第一季到 2018 年第一季是下降的,但你們在開場談話中提到庫存其實已經改善。所以我的問題是,那項揭露到底代表什麼意思?我之所以問,是因為——投資人過去非常在意這項揭露,因為 Salix 過去曾有一些歷史遺留問題。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Sure. So let's start with the headwind, tailwind on FX. And Paul, why don't you talk to that comment. And then we'll go to the Salix.

    好的。那我們先從外匯的逆風、順風談起。Paul,你來回應一下這個問題。然後我們再談 Salix。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sure. I'll start by speaking -- when we talk about the tailwind, the tailwind is Q1 of '18 v 2 1 -- excuse me, Q1 of '17, I can't speak to the characteristics of anybody else's business, but the mix of our business, with the way currency's moved between here and there, it was a circa $65 million tailwind to our results. In other words, if you take that out of the equation and go to a constant currency, if we reported 5%, it's not 5%, it's less than that on a constant-currency basis. And so again, can't speak to how that would affect other companies' -- their portfolio and, in particular, mix of revenues across currencies, but that is how it played out for us on a translational basis. When we talk about the headwinds, the point where I talk about headwinds was with respect to forward-looking, with respect to the guidance. You see on the -- you can see on the chart that shows those -- the waterfall and the progression from last guidance in February to where we are today, since that time, there are substantial unfavorable movements in rates that cause us to reduce our forecast for the full year 2018. I mean, for our company -- every company is different, but for us, the 3 currencies that make a real difference to us are the euro, the Polish zloty and the Chinese yuan. And in those cases, if you look at -- if you go and do the charts from February when we provided our guidance to today, you see that it changed pretty dramatically. We called it -- that was a $70 million headwind at the top. And as I -- in my prepared remarks, it was less than that down below simply because, through Q1, we had actually realized in adjusted EBITDA a $25 million gain. And that was offset by the headwinds that we expect through the entirety of 2018 relative to our guidance -- prior guidance.

    好的。我先說明——當我們談到順風時,這個順風是指 2018 年第一季相較於 2017 年第一季——我無法評論其他任何公司業務的特性,但就我們的業務組合而言,配合匯率在兩個期間之間的變動,對我們的結果大約帶來 6,500 萬美元的順風。換句話說,如果把這個因素排除、改用固定匯率(constant currency)來看,假設我們報告的是 5%,那在固定匯率基礎上就不是 5%,而是低於那個數字。因此,再次強調,我無法評論這會如何影響其他公司的——其產品組合,特別是跨不同幣別的營收組合,但就我們而言,換算(translation)層面就是這樣呈現的。當我們談到逆風時,我提到逆風的情境是針對前瞻性、也就是針對財測(guidance)。你可以在——你可以在那張圖上看到——顯示瀑布圖(waterfall)以及從二月上一次財測到今天的推進變化;自那之後,匯率出現了顯著不利的變動,導致我們下修 2018 全年的預測。我的意思是,對我們公司而言——每家公司都不同,但對我們影響最大的 3 種貨幣是歐元、波蘭茲羅提以及人民幣。在這些情況下,如果你去看——如果你把我們在二月提供財測時到今天的匯率走勢畫成圖,你會看到變化相當劇烈。我們把它稱為營收端(top line)約 7,000 萬美元的逆風。而如我——在事先準備的發言中提到的,往下到調整後 EBITDA 的影響小於這個數字,原因只是因為在第一季期間,我們其實已在調整後 EBITDA 層面實現了 2,500 萬美元的收益。而這個收益被我們預期在 2018 全年、相對於先前財測所面臨的逆風所抵銷。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Let me take the second question, and I think it was related to some of the revision of the contractual terms and trying to understand Salix. I think, let me step back a bit. What happened was this. I think there was a number of really positive things that happened. First, on the volume side, if you follow the weekly prescription numbers through March, you know that total RXs were up 6.8%. Importantly, within that, there's a couple of things that went on beyond that. The -- now beyond that, we also saw increases in the refill rates, mostly behind the hepatic encephalopathy patients where they're getting incremental refills that we think our compliance program have helped us significantly there with the volume side. We did see some incremental pricing that occurred. I remind you that the net pricing for Salix, over the year -- we took approximately a 9% price increase over the year on the pricing side. And the final area was -- really was related to our non-retail channel. In the non-retail channel, we had some contract terms that -- or pricing items related -- and non -- what I'd call, channel dynamics that allowed us to sell more profitable XIFAXAN into the channel, into this non-retail channel. So we had some positives going on there as well. But it really was a question of the volume increases predominantly, also the effective net price of approximately 9% with the total price adjustments. Obviously, we don't realize all the pricing when we make pricing adjustments and then this, what I refer to as non-retail channel dynamics. The final question, I think, was on Slide 42. And you are correct in that there's 2 dynamics going on. First of all, the net channel months on hand went down from March 31, 2018, to -- versus March 31, 2017. As you can see in March 31, for GI, total was 1.48 months, and then it was 1.39 months. So it decreased. Having said that though, you can also see that there was a difference in -- probably, Paul could best describe that portion of the question.

    讓我來回答第二個問題,我認為這與合約條款的一些修訂以及試圖理解 Salix 有關。我想,先退一步說明一下。事情是這樣發生的。我認為發生了幾件非常正面的事情。首先,在銷量方面,如果你追蹤截至 3 月的每週處方數據,你會知道總處方量(RXs)成長了 6.8%。重要的是,在此之中,還有幾件超出這點的事情在發生。另外——除此之外,我們也看到續配率上升,主要來自肝性腦病變患者,他們有額外的續配;我們認為我們的依從性計畫在銷量端對此有顯著幫助。我們確實也看到一些額外的價格提升。我提醒各位,Salix 的淨價格在一年期間——在定價方面,我們一年內大約調升了 9%。最後一個面向——其實與我們的非零售通路有關。在非零售通路中,我們有一些合約條款——或與定價項目相關——以及非——我所稱的通路動態,使我們能在該通路、也就是這個非零售通路中,銷售更多獲利性更高的 XIFAXAN。因此那邊也有一些正面因素。但主要仍是以銷量增加為主,同時也包括在整體價格調整下約 9% 的有效淨價格提升。顯然,我們在進行價格調整時不會把所有漲價都完全實現,另外還有我所提到的非零售通路動態。最後一個問題,我想是在第 42 張投影片。你說得沒錯,確實有兩個動態在發生。首先,通路淨庫存月數(months on hand)從 2018 年 3 月 31 日相較於 2017 年 3 月 31 日是下降的。如你在 3 月 31 日所見,GI 的總計是 1.48 個月,之後是 1.39 個月。所以是下降了。不過話雖如此,你也可以看到其中存在差異——這部分或許 Paul 最能說明你問題的那一段。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes. Umer, it's a great question because I know with the advent of [AMAs there], you get -- was beautiful. We've got wonderful visibility into what goes on in the wholesale channel. Over time, we have to start looking at the retailers as well, and I called it out in my remarks. I will tell you that in Q1 of 2017, there was a lot of inventory, apparently in the retail channel. We can get at that not with the same degree of specificity that we can for wholesale, but we can get at it by looking at the data of product going out from the wholesalers, match -- trying to match that up against end product demand. And what we saw in Q1 of '17 was a significant reduction of retail pipeline inventories in the year-ago quarter. I described this as -- it's a little bit like whack-a-mole. We got -- we and every other pharma company got good visibility, control over the inventories in wholesale, but the challenge has shifted to keeping an eye on what goes on with some of the larger retailers who tend to sometimes buy product ahead of demand.

    是的。Umer,這是個很好的問題,因為我知道隨著 [AMAs there] 的出現,你會——那真是很棒。我們對批發通路中發生的事情有非常好的能見度。隨著時間推進,我們也必須開始關注零售端,我在我的發言中也特別提到了。我可以告訴你,在 2017 年第一季,零售通路顯然有相當多的庫存。我們無法像對批發那樣以同等精確度掌握,但我們可以透過觀察產品從批發商出貨的數據,並嘗試將其與終端產品需求相匹配來推估。而我們在 2017 年第一季看到的是:相較去年同期,零售管線庫存出現顯著下降。我把這形容為——有點像打地鼠。我們——以及其他所有藥廠——對批發端庫存有了很好的能見度與控制力,但挑戰轉移成要盯緊一些大型零售商的動向,因為他們有時會在需求之前提前買進產品。

  • Operator

    Operator

  • Your next question comes from the line of Greg Fraser with Deutsche Bank.

    下一個問題來自德意志銀行(Deutsche Bank)的 Greg Fraser。

  • Gregory Daniel Fraser - Research Analyst

    Gregory Daniel Fraser - Research Analyst

  • This is Greg Fraser on for Gregg Gilbert. On XIFAXAN, the recent extension of the stay in the patent case, was there any magic behind the length of the extension? Was it set by the court? Was it decided by you or Teva? Just any color on that would be helpful. And then on the rifaximin development programs, sorry if I missed this, but the studies that you mentioned for acute overt HE and SIBO, are those going to use the new formulation?

    我是 Greg Fraser,代替 Gregg Gilbert 提問。關於 XIFAXAN,近期在專利訴訟案中延長暫緩(stay),這個延長期間的長度背後有什麼特別原因嗎?是法院決定的嗎?是你們或 Teva 決定的嗎?任何補充說明都會很有幫助。另外關於 rifaximin 的開發計畫,抱歉如果我漏聽了,但你提到的急性顯性肝性腦病變(acute overt HE)與 SIBO 的研究,是否會使用新的配方?

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Yes. So on the question on the XIFAXAN stay, I guess I'll just back up a little bit on the question, just reiterate. We think we have a strong intellectual property position. We have patents that run through 2029. We like our position with XIFAXAN. As you appropriately pointed out, we had previously given originally Actavis, now known as Teva, a 1-year stay on this in terms of negotiation discussions with the court. That stay expired in April. The -- there was a request for an additional 90-day stay on this case. We obviously agreed to that in belief that nothing really has changed. So for that reason, we feel very good about our intellectual property position, and we believe, as I said in the call, that there is no -- at this time, no ANDA that's been filed that we believe is approvable based on the requirements that are required for a XIFAXAN generic equivalent. But we'll wait [for their] conversations and see where it goes from this, but we did grant an additional 90-day -- or agreed to an additional 90-day stay on the case. On the question of OHE, overt hepatic encephalopathy plus SIBO, we are running the new indications with a new formulation. We have published the new clinical trial protocol on clinicaltrials.gov. It's out there, and you'll see it is a new formulation for the treatment of -- starting with the OHE, and we'll have more to say about the SIBO at some point in the near future.

    是的。關於 XIFAXAN 暫緩(stay)的問題,我想先稍微回到問題本身再重申一下。我們認為我們的智慧財產權地位很強。我們的專利有效期一路到 2029 年。我們對 XIFAXAN 的立場很有信心。如你正確指出的,我們先前在與法院的協商討論中,原本給了 Actavis(現稱 Teva)為期 1 年的暫緩。該暫緩在 4 月到期。之後有人提出要求在此案上再額外暫緩 90 天。我們當然同意了,因為我們相信實際上並沒有任何改變。因此,我們對我們的智慧財產權地位感到非常有把握,而且我們相信——如我在電話會議中所說——截至目前,我們認為並沒有任何已提交的 ANDA 能夠在符合 XIFAXAN 學名藥等效性所需要求的前提下獲得核准。但我們會等待 [他們的] 討論,看看後續發展;不過我們確實核准了額外 90 天——或同意了額外 90 天的暫緩。至於 OHE(顯性肝性腦病變)與 SIBO(小腸細菌過度生長)的問題,我們會以新配方來進行這些新適應症的研究。我們已在 clinicaltrials.gov 上公布新的臨床試驗方案。資料已經公開,你會看到這是用於治療的全新配方——先從 OHE 開始;至於 SIBO,我們會在不久的將來某個時間點提供更多說明。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • There was a question on rifaximin development.

    有人問到 rifaximin 的開發。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Yes, I did that on OHE and SIBO.

    是的,我已經回答了 OHE 和 SIBO 的部分。

  • Operator

    Operator

  • Your next question comes from Chris Schott with JPMorgan.

    下一個問題來自摩根大通(JPMorgan)的 Chris Schott。

  • Christopher Z. Neyor - Analyst

    Christopher Z. Neyor - Analyst

  • This is Chris Neyor on for Chris Schott. First question, with the increase in your 2018 guidance, how should we be thinking about the free cash flow trajectory for the full year? And then on DUOBRII specifically, can you elaborate on how you're thinking about the launch curve dynamics as we move ahead with this opportunity later this year?

    我是 Chris Neyor,代替 Chris Schott 提問。第一個問題,隨著你們上調 2018 年指引,我們應該如何看待全年自由現金流的走勢?另外就 DUOBRII 而言,你能否更詳細說明一下,隨著我們在今年稍晚推進這個機會,你們如何看待上市曲線的動態?

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Okay. Paul, why don't you...

    好的。Paul,你要不要……

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, sure. I'll talk about the cash flow trajectory. Again, as I pointed out in my prepared remarks, based on our original 2018 guidance, and we were talking about prospects for cash flow for 2018, we said we felt like, on a smooth average basis, we generate something in the low $400 millions per quarter. We had a very strong first quarter. I think that low $400 million average over the year continues to hold true. It's certainly helpful when your adjusted EBITDA increases. Obviously, that might nudge that upward. But order of magnitude, I think the low $400 million still maintain -- retains -- it's accurate.

    好的,當然。我來談談現金流走勢。再次如我在事先準備的發言中指出,基於我們原先的 2018 年指引,當時談到 2018 年的現金流展望時,我們表示我們認為以平滑的平均基礎來看,每季可產生約 4 億美元出頭的現金流。我們第一季表現非常強勁。我認為全年平均每季 4 億美元出頭這個水準仍然成立。當你的調整後 EBITDA 增加時,當然會有所助益。顯然,這可能會把數字往上推一些。但就量級而言,我認為每季 4 億美元出頭仍然維持——仍然——是準確的。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • And then on DUOBRII, the question is where are we, what are our expectations. Well, I think, with any new launch, you have to realize that new launches today have to go through the appropriate managed care market access discussions. We have had good progress with that already. Our hope and our belief is that managed care market access physicians will recognize that DUOBRII offers patients really a game changer in the concept of now we will have a topical treatment for psoriasis, which is what people were looking for, that has the potential to be used for a longer duration than what currently -- high-potency corticosteroids can be used for only approximately 2 weeks. We believe we have an opportunity to give patients benefits for a longer duration. And obviously, awaiting PDUFA date from discussions with the FDA, but we're excited about what that means over the long term. We would say though that with any new product, at least because of some of the new-to-market blocks, ramp is somewhat slower than it used to be historically. But we think we have an important advance for patients and for physicians in the treatment of -- topical treatment of psoriasis.

    接著談到 DUOBRII,問題在於我們目前進展到哪裡、我們的預期是什麼。我認為,任何新產品上市都必須認知到,如今的新上市產品都需要經過適當的受管理醫療(managed care)市場准入(market access)討論。我們在這方面已經取得不錯的進展。我們的希望與信念是,受管理醫療市場准入端的醫師會認同 DUOBRII 對病患而言確實是個改變遊戲規則的產品:因為現在我們將有一種治療乾癬的外用療法——這正是大家一直在尋找的——而且它有潛力可使用更長的療程;相較之下,目前的高效力皮質類固醇大約只能使用 2 週。我們相信我們有機會讓病患在更長期間內獲得效益。當然,我們仍在等待與 FDA 討論後的 PDUFA 日期,但我們對其長期意義感到振奮。不過我們也會說,任何新產品至少因為一些新上市的阻礙因素,爬坡速度會比過去歷史上稍慢一些。但我們認為,對病患與醫師在乾癬的外用治療上,這是一項重要的進展。

  • Operator

    Operator

  • Your next question comes from the line of David Risinger with Goldman Sachs (sic) [Morgan Stanley].

    下一個問題來自 David Risinger,任職於高盛(誤)[摩根士丹利]。

  • David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

    David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

  • Actually, it's Dave Risinger from Morgan Stanley. So a couple of questions. First of all, with respect to the organic revenue growth, obviously, that was nice to see and compelling this quarter and boosted by XIFAXAN. Could you talk about the prospects looking forward for organic revenue growth? Second, with respect to XIFAXAN, just so that we're level setting appropriately, how should we think about the second quarter sequential sales prospects versus the $276 million that was reported in the first quarter? And then third, when do you expect to start to disclose new product quarterly sales?

    其實我是摩根士丹利的 Dave Risinger。我有幾個問題。首先,關於有機營收成長,顯然本季看到這個表現令人欣慰且具吸引力,而 XIFAXAN 也帶來了助益。能否談談未來有機營收成長的展望?第二,關於 XIFAXAN,為了讓我們能正確校準預期,對於第二季相較第一季所報告的 2.76 億美元,序列(sequential)銷售展望應該如何看待?第三,你們預計何時開始揭露新產品的季度銷售額?

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Okay. Let me start with the first comment on organic growth. And I think one of the important comments -- and thank you for noticing. One important comment is, when you have a turnaround, the first thing you need to do is stabilize the company and then focus on turning it around and starting to show organic growth. We did indeed show that 2% organic growth, the first time since 2015. So feel very excited about that. But I think the other piece that I made mention of in the call that I think is an important factor is that, if you take our top 10 products, obviously, our most important products, during -- looking at those, the top 10 products grew by 20% versus last year. So I think that, that's an important indicator of this turnaround process that we have underway. There's always going to be some quarterly variations, and we don't really comment specifically about quarters in terms of where things are going. But I think the momentum we have in these top 20 products, I think, is probably the best leading indicator of what we're trying to accomplish. Once again, on XIFAXAN, we don't really talk about the specifics of the quarterly sales numbers. But obviously, as you look at the prescription levels versus where we are, I think, as Mark just said in his comments, we have hit an all-time record as we have just -- the latest weekly results for an all-time record for XIFAXAN. We're up approximately 6.8%, I think, year-to-date, 7% year-to-date. So it obviously gives us very comfortable feelings on our growth potential versus a year ago as we approach the second quarter and beyond in terms of where we're going with business. But we can't really make any more specific comments about guidance for -- quarterly guidance on products. And I think the final question, when will we disclose new product sales, our view on new products sales is that we give updates on prescriptions, but, actually, we don't report on new product sales until they achieve the status being one of the top 10 products as we disclose top 10 products in each of our therapeutic segments. The good news is that, with the second quarter, we'll provide even greater clarity because we'll start reporting Bausch + Lomb/International, we will start -- we're reporting Salix, and we will be reporting the dermatology business all as separate entities as well as diversified. So you'll see even greater clarity on what's happening with our overall sales. We hope that transparency helps you in your modeling.

    好的。我先從第一點——有機成長——開始。我想其中一個重要的評論——也謝謝你注意到。一個重要觀點是,當你在做轉型(turnaround)時,第一件事是先穩定公司,然後專注於扭轉局面並開始展現有機成長。我們確實達成了 2% 的有機成長,這是自 2015 年以來的第一次。因此我們對此感到非常振奮。但我認為我在電話會議中提到的另一個重點、也是重要因素是:如果你看我們前 10 大產品——顯然是我們最重要的產品——在這些產品中,前 10 大產品相較去年成長了 20%。所以我認為,這是我們正在進行的轉型過程的一個重要指標。季度之間總會有一些波動,我們通常不會就各季度的走向做具體評論。但我認為,我們在前 20 大產品上的動能,可能是我們想達成目標的最佳領先指標。再談 XIFAXAN,我們不會談季度銷售數字的細節。但顯然,當你看處方量的水準與我們目前的位置,正如 Mark 在他的評論中所說,我們剛剛——最新的每週結果——創下了 XIFAXAN 的歷史新高紀錄。我們年初至今約成長 6.8%,我想是年初至今 7%。因此,當我們邁向第二季及之後、就業務走向而言,這顯然讓我們對相較一年前的成長潛力感到非常踏實。但我們無法再就——產品的季度指引——提供更具體的評論。最後一個問題:何時會揭露新產品銷售?我們對新產品銷售的看法是,我們會更新處方數據,但實際上,在新產品達到前 10 大產品的地位之前,我們不會報告其銷售;我們會在各治療領域的分部中揭露前 10 大產品。好消息是,從第二季開始,我們會提供更高的透明度,因為我們將開始把 Bausch + Lomb/International 分開揭露,我們也會——揭露 Salix,並且把皮膚科業務也作為獨立實體揭露,同時也會有 diversified(多元化)項目。因此你將更清楚看到我們整體銷售的變化。我們希望這樣的透明度能幫助你進行模型推估。

  • Operator

    Operator

  • Your next question comes from the line of Louise Chen with Cantor Fitzgerald.

    下一個問題來自 Cantor Fitzgerald 的 Louise Chen。

  • Jennifer M. Kim - Analyst

    Jennifer M. Kim - Analyst

  • This is Jennifer on for Louise. I have a couple here. First, just going back to derm. A lot of companies in the derm space seem to continue having some difficulty getting candidates to approval. So I'm just wondering, as a larger and, I guess, more experienced key player, can you talk about what drives your confidence in getting your key pipeline candidates to approval? And then related to that, I think -- on 120, I think, originally, Phase III was expected to initiate in the first half of 2018, and now it's second half. And I'm just wondering if you could give a bit more color on the reasoning behind that. And then my second question is just on Vyzulta. I know it's very early, but do you have any color on how much -- how the uptake has been, or has it been driven more by market growth or like what you're -- what the feedback you've been hearing from patients is so far?

    我是 Jennifer,代 Louise 提問。我這裡有幾個問題。首先,回到皮膚科(derm)。皮膚科領域的許多公司似乎仍在讓候選產品獲得核准方面遇到一些困難。所以我想請教,作為一家規模更大、我想也更有經驗的關鍵參與者,你們能否談談是什麼驅動你們對於讓核心管線候選產品取得核准的信心?另外與此相關,我想——關於 120,我記得原本預期第三期(Phase III)會在 2018 年上半年啟動,但現在變成下半年。我想請你們多提供一些背景,說明背後原因。第二個問題是關於 Vyzulta。我知道現在還很早,但你們是否能分享一些資訊——例如採用/滲透(uptake)大概如何,或是它更多是由市場成長所帶動,或是到目前為止你們從病患那裡聽到的回饋是什麼?

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Sure. So let me start with your derm question. I think the question in terms of our ability to get approvals stems from really just one major fact: we just have a great dermatology R&D team. They've done just phenomenal relative not only to existing portfolio of products we have but also these new products. They really know how to develop these products. They know how to show the benefits. And I think as we look at what we're doing with products like DUOBRII, ALTRENO, BRYHALI, we think these are the types of products that we feel very comfortable, based on our interactions with FDA, that we are delivering NDAs that are showing the appropriate studies that will generate the approval. I will say that we put a statistic in based on -- I think it was last quarter, that this team, the team that previously was known as Dow, which is part of Valeant and the Ortho Dermatologics team, is responsible for a significant portions of all of -- many of the products that have been developed not just here at Valeant but even prior to Valeant's acquisition of this business that [developed] -- made these dermatologic products. So they truly are a center of excellence. On the question of IDP-120 moving from first half to second half, that's really just a slight timing variation. No big issues with the product or what we are expecting. It's just really moving through the clinical trial process, there's a slight change in the timing. Vyzulta, we're excited. We continue to see the numbers of prescriptions that are being written for Vyzulta continue to climb. So we're excited about that. As we said at the beginning of the launch, we -- 2018 is an important year to get it up and running. But we do know we need to get the Part D coverage, and that's something we're working on right now. So that's why the end of the -- this 2018 time frame, entering into 2019, we'll have an appropriate coverage across the entire spectrum of our opportunities. So excited about what it means. We're getting great feedback about this dual mechanism of action with Vyzulta and what it means for patients in terms of patient benefits. So we'll continue to make progress there with the belief that we'll need to do some additional contracting. Much of that is well underway already for an even better 2019.

    當然。那我先從您關於皮膚科的問題開始。我認為,關於我們取得核准的能力,這個問題主要源自一個關鍵事實:我們擁有一支非常出色的皮膚科研發團隊。他們的表現非常卓越,不僅相較於我們現有的產品組合,也包括這些新產品。他們非常懂得如何開發這些產品。他們也知道如何呈現其效益。而且我認為,當我們看像 DUOBRII、ALTRENO、BRYHALI 這類產品時,基於我們與 FDA 的互動,我們對於自己所提交的 NDA 很有信心,因為其中包含了適當的研究,能夠促成核准。我想補充的是,我們曾引用一項統計數據——我記得是在上一季——這個團隊,先前被稱為 Dow 的團隊(屬於 Valeant 的一部分)以及 Ortho Dermatologics 團隊,負責了相當大一部分的產品開發;不僅是在 Valeant 這裡,甚至在 Valeant 收購這項業務之前,這些團隊就已經[開發]並推出了這些皮膚科產品。所以他們確實是一個卓越中心。至於 IDP-120 從上半年移到下半年,這其實只是時間上的些微變動。產品本身或我們的預期沒有重大問題。只是臨床試驗流程推進中,時程略有調整。至於 Vyzulta,我們很興奮。我們持續看到 Vyzulta 的處方數量不斷攀升。所以我們對此感到振奮。正如我們在上市之初所說,2018 年是讓它順利啟動並運轉起來的重要一年。但我們也知道需要取得 Part D 的給付涵蓋,這也是我們目前正在努力的方向。因此在 2018 年底、進入 2019 年時,我們將能在整個機會版圖上取得適當的涵蓋。所以我們對其意義感到興奮。我們也收到關於 Vyzulta 這種雙重作用機轉的正面回饋,以及它對病患在效益上的意義。因此我們會持續推進,並相信我們需要進行一些額外的合約談判。其中許多工作其實已經在積極進行中,為 2019 年帶來更好的表現。

  • Operator

    Operator

  • Your last question comes from the line of David Amsellem with Piper Jaffray.

    您最後一個問題來自 Piper Jaffray 的 David Amsellem。

  • David A. Amsellem - MD and Senior Research Analyst

    David A. Amsellem - MD and Senior Research Analyst

  • And I know you're not breaking out SILIQ just yet, but maybe talk qualitatively to the payer landscape here and just going forward, how heavily contracted you think the product's going to be. And in terms of how it's being used, I mean, are you finding that you're seeing significant number of patients who have already cycled through Cosentyx and Taltz? Just talk about those dynamics, if you can.

    我知道你們目前還不打算單獨揭露 SILIQ 的數據,但能否從質性角度談談目前的支付方環境,以及往後你們認為這個產品會被多大程度地納入合約(重度簽約)?另外就使用情況而言,我的意思是,你們是否發現有相當多的病患已經在 Cosentyx 和 Taltz 之間輪替使用過?如果可以的話,請談談這些動態。

  • Joseph C. Papa - CEO & Chairman

    Joseph C. Papa - CEO & Chairman

  • Sure. So SILIQ, we continue to make progress. As I mentioned in the call, we have more than 2,500 doctors REMS certified. Because of what we did on the pricing of SILIQ, we priced it, we think, very cost-effectively for managed care plans in the -- 10-plus-percent reduction from existing injectable biologics, depending -- [it could be] even more than that, depending on how one quantifies it. We have gotten a good reception. To date, we have 49% of commercially insured patients that have been covered, so we're getting good coverage so far. Obviously, that will continue to improve as we make progress with the managed care plans. I think the important issue for us is that -- 2 things on SILIQ. Number one, we're getting a great response from those physicians that have been REMS certified. They wouldn't go through REMS certification if they did not believe there was a space in their armamentarium for use of SILIQ. So physicians are responding well and going through REMS certification. We have an all-time record in terms of number of new patients coming into the process. We -- week over week, we continue to climb on the TRx side. I think the actual number of REMS-certified physicians actually is now up to like 2,719. We're increasing the number of calls we're making. As a reminder, we launched this with a very limited, almost like a SWAT team of sales reps going in to get to the key opinion leaders and also the docs that were part of the clinical trial. We've now expanded it to a full team in the treatment of psoriasis team calling on those docs. So completely new approach as of January, based on the fact that we first have to get through REMS certification. We've done that. Now we're starting to see the benefits of that for the patients, and we're excited about where that goes for the future.

    當然。關於 SILIQ,我們持續取得進展。如我在電話會議中提到的,我們已有超過 2,500 位醫師完成 REMS 認證。由於我們對 SILIQ 的定價策略,我們將其定價設定為對管理式醫療計畫非常具成本效益——相較於現有可注射生物製劑,價格降低了 10% 以上;視——[也可能]依不同的衡量方式而更高。我們獲得了良好的回應。截至目前,我們已覆蓋 49% 的商業保險病患,因此目前的給付涵蓋進展不錯。當然,隨著我們在管理式醫療計畫上的推進,這還會持續改善。我認為對我們而言,SILIQ 有兩個重點。第一,我們從那些已完成 REMS 認證的醫師那裡得到非常好的回饋。如果他們不認為 SILIQ 在其治療工具箱中有一席之地,他們不會去完成 REMS 認證。因此醫師反應良好並持續完成 REMS 認證。在新病患進入流程的數量方面,我們創下歷史新高。我們——在 TRx(總處方量)方面,週週持續攀升。我想目前 REMS 認證醫師的實際數量已經上升到大約 2,719 位。我們也在增加外呼拜訪的次數。提醒一下,我們上市初期採用的是非常精簡、幾乎像 SWAT 小組的業務代表團隊,去接觸關鍵意見領袖以及參與臨床試驗的醫師。現在我們已擴編為完整的乾癬治療業務團隊,去拜訪這些醫師。因此自一月起,我們採取了全新的做法,因為我們首先必須完成 REMS 認證這一關。我們已經做到這點。現在我們開始看到這對病患帶來的效益,我們也對未來的發展感到興奮。

  • Thank you, everyone, for joining us today. Thank you very much for your interest in Valeant. Have a great day, everyone.

    感謝各位今天加入我們。非常感謝各位對 Valeant 的關注。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference call. You may now disconnect.

    今天的電話會議到此結束。您現在可以掛線。